GSK
GSK
806 hedge funds and large institutions have $12.1B invested in GSK in 2019 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 278 increasing their positions, 286 reducing their positions, and 68 closing their positions.
28% more call options, than puts
Call options by funds: $147M | Put options by funds: $115M
10% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 68
8% more capital invested
Capital invested by funds: $11.2B → $12.1B (+$883M)
0% more funds holding
Funds holding: 804 → 806 (+2)
0.05% more ownership
Funds ownership: 4.48% → 4.53% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
3% less repeat investments, than reductions
Existing positions increased: 278 | Existing positions reduced: 286
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$94.2M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$77.5M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$61.2M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$58.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$46.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$56.1M |
| 2 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$54.8M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$49.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.8M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
-$41.8M |
GSK Hedge Fund Activity: Q3 2019 in Review
806 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2019, worth a combined $12.1B — up 7.9% from $11.2B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new GSK positions and 68 closed out — a net gain of 7 holders — while 278 added to existing stakes and 286 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $94.2M. The largest seller was Deutsche Bank, cutting an estimated $56.1M.
- 806 institutional investors held GSK (GSK) as of Q3 2019, up from 804 in Q2 2019.
- Funds reported $12.1B of GSK stock for Q3 2019, up 7.9% quarter-over-quarter.
- 75 funds opened new GSK positions in Q3 2019 and 68 closed out, a net change of +7 holders.
- The largest GSK buyer in Q3 2019 was Renaissance Technologies, an estimated $94.2M added.
- The largest GSK seller in Q3 2019 was Deutsche Bank, an estimated $56.1M sold.
Based on aggregated 13F filings for Q3 2019.